Drug intelligence / Profile preview

4025-A

Development stage: Unknown
Lead developer: Shanghai Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

4025-A (also known as SPH4025) is an investigational small molecule potassium-competitive acid blocker (P-CAB) developed by Shanghai Pharmaceuticals Holding Co., Ltd. for the treatment of digestive system diseases, specifically acid-related disorders such as reflux esophagitis. Unlike traditional proton pump inhibitors (PPIs) that require acid activation and bind irreversibly to the H+/K+-ATPase enzyme, 4025-A inhibits the proton pump in a reversible and potassium-competitive manner. This mechanism allows for a more rapid onset of action, consistent acid suppression, and improved control of nocturnal acid breakthrough compared to conventional therapies. The drug is currently in Phase 2 clinical development.

Other names: 4025ASPH4025SPH-4025SPH 4025

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on 4025-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4025-A.

Explore the full profile